Targeting immune checkpoints such as CTLA4, PD1 and PD-L1 has produced impressive results across a diverse variety of malignancies including AML through immunoinhibitory signal blockage and CD8+ T-cell activation to initiate a strong antitumor response (Figure 1A). This evidence concerns the gene PDCD1 and acute myeloid leukemia.